Offline mode

Borrelia burgdorferi, a bacterium of the Spirochaetaceae, is the ethiologic agent of Lyme disease (Borreliosis) being the most common disease in Europe and the USA transmitted by tics (Ixodes sp.). Lyme borreliosis is a multi-systemic disease with a broad spectrum of clinical symptoms. A typical symptom of the acute phase is the erythema chronicum migrans (ECM), often accompanied by flue-like symptoms. In later stages of the disease arthritis, carditis, as well as neurological and dermatological manifestations may occur. Lyme borreliosis can be treated with antibiotics in all stages. Therefore, a safe and sensitive laboratory diagnosis of Lyme borreliosis, also detecting the early stage of diseases, is of major importance, since an early treatment is most appreciated. IgM antibodies usually appear approximately three weeks after the infection, IgG antibodies after four to six weeks. The early immune reaction is mainly directed against the flagellin peptide (41 kDa) and the OspC (Outer surface protein C, 23 kDa) and is then spread on more and more bacterial proteins. In this test Borrelia burgdorferi-specific 14 kDa fragment of the flagellin is used as a recombinant protein for antibody binding. This recombinant, in E. coli produced flagellin fragment is found to be identical in all three subspecies of borrelia. Results of extensive comparative studies with ELISA, IFA and agglutination tests as well as Western Blot demonstrate that the 14kDa IgM ELISA shows a higher diagnostic specificity as well as an increased sensitivity for the early immune response in Lyme borreliosis. In addition to the recombinant 14 kDa flagellin fragment the native OspC protein is used as coating antigen in the IBL Borrelia 14kDa + OspC IgM ELISA. Usually the acute phase is indicated by high titers of IgM antibodies. High IgG titers with low or without IgM antibodies occur when borreliosis is subsiding (due to therapy or spontaneously) or during the chronic stage. The Borrelia IgM test can be used for the diagnosis of Lyme borreliosis in the acute and chronic stage of the disease both requiring a therapy. Patients with a subsided borreliosis which does not require therapy any more will not show positive results.

For concrete data please consult the Instruction for Use in the download box on the top right side.

Our Product Families

Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.

And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.

All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use. 

All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).

Image on background

This is who we are.

As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.

Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.

Happy to help.

At Tecan, we are driven to improve people’s lives and health.